Scilex Holding Company (SCLX) AI Stock Analysis

Scilex Holding Company is a biopharmaceutical firm that develops and commercializes non-opioid pain management solutions. Its primary commercial product is ZTlido 1.8%, an advanced prescription lidocaine topical product designed to relieve neuropathic pain linked to post-herpetic neuralgia from post-shingles nerve damage. The company is advancing several pipeline candidates, including SP-102, a viscous gel formulation of corticosteroid in Phase III trials for lumbosacral radicular pain. Its pipeline also features SP-103 in Phase II trials for low back pain and SP-104, which completed Phase I clinical trials for fibromyalgia. Scilex operates as a subsidiary of Sorrento Therapeutics, Inc.

Scilex achieved a 5-year revenue compound annual growth rate of 5.1% from FY2020 to FY2025. Annual revenue expanded from $31.3M in FY2021 to $38.0M in FY2022, $46.7M in FY2023, and peaked at $56.6M in FY2024 before dropping 46.5% to $30.3M in FY2025. Gross margin shrank from 88.4% in FY2021 to 49.7% in FY2025. Operating margin worsened from -114.4% in FY2021 to -900.1% in FY2025, producing a net income of -$358.7M and EPS of -$31.61. For the latest quarter ended June 30, 2026, quarterly revenue fell 22.8% year-over-year, while trailing twelve month operating margin stood at -385.0% on $31.6M in revenue.

As of June 30, 2026, Scilex held $581,000 in cash and short-term investments against total debt of $95.6M, leaving net debt at $95.0M. The company maintains negative shareholders' equity of -$308.3M and total assets of $253.6M, with a current ratio of 0.07. In FY2025, operating cash flow was $3.8M and free cash flow was $3.7M, after capital expenditures of $133,000. Additionally, the company's share count increased 58.4% over five years.

Scilex trades at a forward P/E of 5.6x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 0.6x, below the US-listed Healthcare peer median of 4.1x, while its EV-to-revenue ratio sits at 4.2x. The company holds an enterprise value of $133.4M against a market capitalization of $19.9M and a price-to-book ratio of 28.9x. Over the past year, the stock fell 65.8% and dropped 62.7% year-to-date, trailing the S&P 500 return of 16.8% over the past year.

Wall Street coverage includes a mean price target of $490.00, representing an upside of 17214.5% above the last close of $2.83. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.89 with revenue of $0. For the next fiscal year, 1 analyst expects revenue of $189.0M, reflecting growth of 186.3%, and an EPS of $0.73. The company recorded 0 EPS beats over the last 4 quarters, and its next earnings date is November 13, 2026.

This page is an AI-written research summary of Scilex Holding Company (SCLX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SCLX income statement, SCLX balance sheet, SCLX key metrics, SCLX analyst forecast, SCLX chart. See the SCLX stock overview for the latest quote and news.